Effects of short-term endurance exercise training on acute doxorubicin-induced FoxO transcription in cardiac and skeletal muscle

Journal of Applied Physiology

Volumn 117, Issue 3, 2014, Pages 223-230

  Kavazis, Andreas N ^a   Smuder, Ashley J ^b   Powers, Scott K ^b  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Doxorubicin; Exercise; Reactive oxygen species; Skeletal muscle

Indexed keywords

BNIP3 PROTEIN, RAT; DOXORUBICIN; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, RAT; FOXO3A PROTEIN, RAT; MEMBRANE PROTEIN; MESSENGER RNA; MITOCHONDRIAL PROTEIN; MUSCLE PROTEIN; NERVE PROTEIN; PPARGC1A PROTEIN, RAT; TRANSCRIPTION FACTOR; TRIM63 PROTEIN, RAT; UBIQUITIN PROTEIN LIGASE;

ANIMAL; ANIMAL EXPERIMENT; DRUG EFFECTS; ENDURANCE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETICS; HEART; MALE; PHYSIOLOGY; RAT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT;

ANIMALS; DOXORUBICIN; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HEART; MALE; MEMBRANE PROTEINS; MITOCHONDRIAL PROTEINS; MUSCLE PROTEINS; MUSCLE, SKELETAL; NERVE TISSUE PROTEINS; PHYSICAL CONDITIONING, ANIMAL; PHYSICAL ENDURANCE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; UBIQUITIN-PROTEIN LIGASES;

EID: 84905502462     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.00210.2014     Document Type: Article

References (57)

1. Allen DL, Unterman TG. Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am J Physiol Cell Physiol 292:C188-C199, 2007.
2. Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O, Ahmad F, Matsui T, Chin S, Wu PH, Rybkin II, Shelton JM, Manieri M, Cinti S, Schoen FJ, Bassel-Duby R, Rosenzweig A, Ingwall JS, Spiegelman BM. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 1:259-271, 2005.
3. Ascensao A, Magalhaes J, Soares JM, Ferreira R, Neuparth MJ, Marques F, Oliveira PJ, Duarte JA. Moderate endurance training prevents doxorubicin-induced in vivo mitochondriopathy and reduces the development of cardiac apoptosis. Am J Physiol Heart Circ Physiol 289:H722-H731, 2005.
4. Baar K, Wende AR, Jones TE, Marison M, Nolte LA, Chen M, Kelly DP, Holloszy JO. Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. FASEB J 16:1879-1886, 2002.
5. Bayod S, Del Valle J, Lalanza JF, Sanchez-Roige S, De Luxan-Delgado B, Coto-Montes A, Canudas AM, Camins A, Escorihuela RM, Pallas M. Long-term physical exercise induces changes in sirtuin 1 pathway and oxidative parameters in adult rat tissues. Exp Gerontol 47:925-935, 2012.
6. Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 23:15-25, 2007.
7. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, De Chiara TM, Stitt TN, Yancopoulos GD, Glass DJ. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294:1704-1708, 2001.
8. 3 to trigger Bnip3-dependent cardiomyocyte atrophy. J Am Heart Assoc 2:e000016, 2013.
9. Chicco AJ, Schneider CM, Hayward R. Exercise training attenuates acute doxorubicin-induced cardiac dysfunction. J Cardiovasc Pharmacol 47:182-189, 2006.
10. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 62:4592-4598, 2002.
11. Crow MT. Hypoxia, BNip3 proteins, and the mitochondrial death pathway in cardiomyocytes. Circ Res 91:183-185, 2002.
12. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 261:3060-3067, 1986.
13. De Lange P, Moreno M, Silvestri E, Lombardi A, Goglia F, Lanni A. Fuel economy in food-deprived skeletal muscle: signaling pathways and regulatory mechanisms. FASEB J 21:3431-3441, 2007.
14. Dodd SL, Gagnon BJ, Senf SM, Hain BA, Judge AR. Ros-mediated activation of NF-kappaB and Foxo during muscle disuse. Muscle Nerve 41:110-113, 2010.
15. Doroshow JH. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res 43:4543-4551, 1983.
16. Elliott B, Renshaw D, Getting S, Mackenzie R. The central role of myostatin in skeletal muscle and whole body homeostasis. Acta Physiol (Oxf) 205:324-340, 2012.
17. Ertunc M, Sara Y, Korkusuz P, Onur R. Differential contractile impairment of fast- and slow-twitch skeletal muscles in a rat model of doxorubicin-induced congestive heart failure. Pharmacology 84:240-248, 2009.
18. Gilliam LA, Ferreira LF, Bruton JD, Moylan JS, Westerblad H, St Clair DK, Reid MB. Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. J Appl Physiol 107:1935-1942, 2009.
19. Gilliam LA, Fisher-Wellman KH, Lin CT, Maples JM, Cathey BL, Neufer PD. The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle. Free Radic Biol Med 65:988-996, 2013.
20. Gilliam LA, Moylan JS, Ann Callahan L, Sumandea MP, Reid MB. Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy. Muscle Nerve 43:94-102, 2011.
21. Gilliam LA, Moylan JS, Ferreira LF, Reid MB. TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness. Am J Physiol Lung Cell Mol Physiol 300:L225-L231, 2011.
22. Gilliam LA, Moylan JS, Patterson EW, Smith JD, Wilson AS, Rabbani Z, Reid MB. Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes. Am J Physiol Cell Physiol 302:C195-C202, 2012.
23. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 98:14440-14445, 2001.
24. Gustafsson AB. Bnip3 as a dual regulator of mitochondrial turnover and cell death in the myocardium. Pediatr Cardiol 32:267-274, 2011.
25. Ji LL, Mitchell EW. Effects of adriamycin on heart mitochondrial function in rested and exercised rats. Biochem Pharmacol 47:877-885, 1994.
26. Kang YJ, Chen Y, Yu A, Voss-McCowan M, Epstein PN. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest 100:1501-1506, 1997.
27. Kavazis AN, Smuder AJ, Min K, Tumer N, Powers SK. Short-term exercise training protects against doxorubicin-induced cardiac mitochondrial damage independent of HSP72. Am J Physiol Heart Circ Physiol 299:H1515-H1524, 2010.
28. Lawler JM, Powers SK, Hammeren J, Martin AD. Oxygen cost of treadmill running in 24-month-old Fischer-344 rats. Med Sci Sports Exerc 25:1259-1264, 1993.
29. Lee HK, Rocnik E, Fu Q, Kwon B, Zeng L, Walsh K, Querfurth H. Foxo/atrogin induction in human and experimental myositis. Neurobiol Dis 46:463-475, 2012.
30. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. Peroxisome proliferator-Activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106:847-856, 2000.
31. Lin A, Yao J, Zhuang L, Wang D, Han J, Lam EW, Network TR, Gan B. The FoxO-BNIP3 axis exerts a unique regulation of mTORC1 and cell survival under energy stress. Oncogene 33:3183-3194, 2014.
32. Lu P. Monitoring cardiac function in patients receiving doxorubicin. Semin Nucl Med 35:197-201, 2005.
33. 3 and mTOR in the regulation of autophagy in skeletal muscle. Autophagy 4:524-526, 2008.
34. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387:83-90, 1997.
35. Murton AJ, Constantin D, Greenhaff PL. The involvement of the ubiquitin proteasome system in human skeletal muscle remodelling and atrophy. Biochim Biophys Acta 1782:730-743, 2008.
36. Papanicolaou KN, Phillippo MM, Walsh K. Mitofusins and the mitochondrial permeability transition: the potential downside of mitochondrial fusion. Am J Physiol Heart Circ Physiol 303:H243-H255, 2012.
37. 2, up-regulates fuel oxidation through expression of OXPHOS system. Hum Mol Genet 14:1405-1415, 2005.
38. Powers SK, Duarte J, Kavazis AN, Talbert EE. Reactive oxygen species are signalling molecules for skeletal muscle adaptation. Exp Physiol 95:1-9, 2010.
39. Puthanveetil P, Wan A, Rodrigues B. FoxO1 is crucial for sustaining cardiomyocyte metabolism and cell survival. Cardiovasc Res 97:393-403, 2013.
40. Ranek MJ, Wang X. Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy. Curr Hypertens Rep 11:389-395, 2009.
41. Salvatorelli E, Guarnieri S, Menna P, Liberi G, Calafiore AM, Mariggio MA, Mordente A, Gianni L, Minotti G. Defective one- or twoelectron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition. J Biol Chem 281:10990-11001, 2006.
42. Sandri M. Protein breakdown in muscle wasting: role of autophagylysosome and ubiquitin-proteasome. Int J Biochem Cell Biol 45:2121-2129, 2013.
43. Sandri M, Barberi L, Bijlsma AY, Blaauw B, Dyar KA, Milan G, Mammucari C, Meskers CG, Pallafacchina G, Paoli A, Pion D, Roceri M, Romanello V, Serrano AL, Toniolo L, Larsson L, Maier AB, Munoz-Canoves P, Musaro A, Pende M, Reggiani C, Rizzuto R, Schiaffino S. Signalling pathways regulating muscle mass in ageing skeletal muscle: the role of the IGF1-Akt-mTOR-FoxO pathway. Biogerontology 14:303-323, 2013.
44. 3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA 103:16260-16265, 2006.
45. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117:399-412, 2004.
46. Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R, Sandri M. Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol 296:C1248-C1257, 2009.
47. Sarvazyan N. Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. Am J Physiol Heart Circ Physiol 271:H2079-H2085, 1996.
48. Schottenfeld D, Beebe-Dimmer JL, Buffler PA, Omenn GS. Current perspective on the global and United States cancer burden attributable to lifestyle and environmental risk factors. Annu Rev Public Health 34:97-117, 2013.
49. Schreiber SN, Emter R, Hock MB, Knutti D, Cardenas J, Podvinec M, Oakeley EJ, Kralli A. The estrogen-related receptor alpha (ERRalpha) functions in PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis. Proc Natl Acad Sci USA 101:6472-6477, 2004.
50. Senf SM, Dodd SL, Judge AR. FOXO signaling is required for disuse muscle atrophy and is directly regulated by Hsp70. Am J Physiol Cell Physiol 298:C38-C45, 2010.
51. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905, 1998.
52. Smuder AJ, Kavazis AN, Min K, Powers SK. Doxorubicin-induced markers of myocardial autophagic signaling in sedentary and exercise trained animals. J Appl Physiol 115:176-185, 2013.
53. Smuder AJ, Kavazis AN, Min K, Powers SK. Exercise protects against doxorubicin-induced markers of autophagy signaling in skeletal muscle. J Appl Physiol 111:1190-1198, 2011.
54. Smuder AJ, Kavazis AN, Min K, Powers SK. Exercise protects against doxorubicin-induced oxidative stress and proteolysis in skeletal muscle. J Appl Physiol 110:935-942, 2011.
55. St-Pierre J, Lin J, Krauss S, Tarr PT, Yang R, Newgard CB, Spiegelman BM. Bioenergetic analysis of peroxisome proliferator-Activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J Biol Chem 278:26597-26603, 2003.
56. Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK. The protective role of manganese superoxide dismutase against adriamycininduced acute cardiac toxicity in transgenic mice. J Clin Invest 98:1253-1260, 1996.
57. Zorzano A. Regulation of mitofusin-2 expression in skeletal muscle. Appl Physiol Nutr Metab 34:433-439, 2009.